Skip to main content
Equibles
OCGN logo

OCGN · Ocugen, Inc. · Metrics

Track OCGN — free

Use OCGN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research OCGN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.81 -0.01 (-0.80%) Play latest call Q3 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Going-concern doubt — flagged Nov 4, 2026

Substantial doubt about the company's ability to continue as a going concern.

“After evaluating these conditions and management’s plans, the Company has concluded that there is substantial doubt about the Company’s ability to continue as a going concern within one year after the date these unaudited condensed consolidated financial statements are issued.”
View the 10-Q filed Nov 4, 2026
Market Cap
$294.01M
Shares
339.31M
Volume · Nov 5 7.15M Avg daily vol (3M) 6.56M

OCGN metrics

72 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.82
Market cap
$294.01M

Price action

20 metrics
Price change (1W)
+12.6%
Price change (30D)
-15.9%
Price change (3M)
-31.7%
Price change (6M)
-39.9%
Price change (YTD)
-35.2%
Price change (1Y)
-38.8%
Trailing year
Price change (5Y)
-91.3%
52-week high
$2.48
52-week low
$0.70
Change from 52-week high
-64.7%
Change from 52-week low
+24.4%
Annualized volatility
80.6%
Annualized volatility (3M)
76.1%
Beta
1.8
RSI (14D)
51.7
Price vs SMA 50
-12.4%
Price vs SMA 200
-38.2%
Avg volume (3M)
6.55M
Relative volume
1.4
Average dollar volume
$6.72M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
339.31M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
56.7×
reciprocal yield 1.8%
EV / EBITDA
—
EV / EBIT
—
P / sales
61.5×
reciprocal yield 1.6%
P / book
—
FCF yield
-21.7%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-22.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
65.7×
reciprocal yield 1.5%
EV / revenue historical average (5Y)
65.7×
reciprocal yield 1.5%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-11-04

Profitability

9 metrics
Gross margin
—
Operating margin
-1,444.5%
Trailing 12 months
Net margin
-1,367.6%
Gross profit (TTM)
—
Operating profit (TTM)
−$69.03M
Net income (TTM)
−$65.36M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
-1,337.2%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-0.04

Growth

11 metrics
Revenue growth YoY
+11.4%
Year over year
Net income growth YoY
—
Revenue (TTM)
$4.78M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+11.6%
Year over year · more shares
Revenue CAGR (3Y)
+21.0%
Revenue CAGR (5Y)
+152.5%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-60.5%
Debt / equity
—
Current ratio
0.8
EBITDA (TTM)
—
Free cash flow (TTM)
−$63.90M
Quick ratio
0.8
Interest coverage
-6.8
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$22.85M
Latest balance sheet
Cash & equivalents
$24.63M
Total assets
$108.06M
Total debt
$1.78M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$63.69M
Capital expenditures (TTM)
$211,000
R&D (TTM)
$45.12M
SG&A (TTM)
—
Stock compensation (TTM)
$959,000
R&D / revenue
944.0%
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
150
13F filer change QoQ
+12
Institutional ownership
43.6%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
13.3%
Private-fund adviser ownership
12.1%
Active holders' share change QoQ
-9.4%
Holder tenure
10.7
Price vs estimated holder cost
-2.5%

Ownership (registered funds)

1 metrics
Index-fund ownership
15.3%

Short interest

3 metrics
Short interest
31.6%
Latest settlement · 15.8 days to cover
Days to cover
15.8d
Short-squeeze score
87 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$1.09M
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1372299 CUSIP 67577C105 13F (30d) 57 filings 44 filers Visit website Investor relations